Showing 1 - 10 of 20
A controversial feature of Medicare Part D is its reliance on private insurers to negotiate drug prices and rebates with retail pharmacies and drug manufacturers. Central to this controversy is whether increases in market power--an undesirable feature in most settings--confer benefits in health...
Persistent link: https://www.econbiz.de/10013156429
Persistent link: https://www.econbiz.de/10003885817
A controversial feature of Medicare Part D is its reliance on private insurers to negotiate drug prices and rebates with retail pharmacies and drug manufacturers. Central to this controversy is whether increases in market power--an undesirable feature in most settings--confer benefits in health...
Persistent link: https://www.econbiz.de/10012463320
Persistent link: https://www.econbiz.de/10003770583
Features of Part D gave rise to broad concern that the drug benefit would negatively impact prescription utilization among the six million dual eligible beneficiaries, either during the transition from state Medicaid to Part D coverage, or in the long-run. At the same time, Part D contained...
Persistent link: https://www.econbiz.de/10012464234
Features of Part D gave rise to broad concern that the drug benefit would negatively impact prescription utilization among the six million dual eligible beneficiaries, either during the transition from state Medicaid to Part D coverage, or in the long-run. At the same time, Part D contained...
Persistent link: https://www.econbiz.de/10012769646
Innovation policy often involves an uncomfortable trade-off between rewarding innovators sufficiently and providing the innovation at the lowest possible price. However, in health care markets with insurance for innovative goods, society may be able to ensure efficient rewards for inventors and...
Persistent link: https://www.econbiz.de/10013240340
Persistent link: https://www.econbiz.de/10008648651
Persistent link: https://www.econbiz.de/10009749348
Persistent link: https://www.econbiz.de/10010425165